Why Sculptra as opposed to Hyaluronic Acid fillers?

Really it is an answer that depends on your age. There are some important concepts about the aging face that all physicians (and clients) should realize:  before the age of 40, the volume loss we see in our faces is mainly due to fat loss, after mid 40’s bone loss becomes prominent. In the pre forty age group volume and wrinkles  can be corrected easily with fillers like hyaluronic acid (Juvederm). Starting in the mid 40’s, with the loss of bone as well, the underlying skeletal structural support in the face begins to breakdown, and facial aging accelerates. This progresses faster for women when after menopause. Subsequently, the way to correct volume loss is different than younger women, focusing more on “imitating bone” with deep, collagen stimulating fillers such as Sculptra or high G prime fillers like Voluma and Restylane Lyft.  The mid-face (cheek) is the most important area to correct, as it restores volume, provides lift, and provides the most youthful beauty to the face. In fact, the majority of how people judge our age is by looking at the middle third of our face (our cheek area). This is where the major effect of Sculptra is concentrated.

*Results may vary from patient to patient


How is Sculptra® different from other fillers? 

Sculptra® is an FDA-approved injectable poly-L-lactic acid that works gradually to give you subtle yet noticeable results that can last up to 2 years. It is a long-acting dermal filler composed of PLLA, a biocompatible and biodegradable polymer, with over 30 years of use in medical products

Sculptra® Aesthetic is different in the way it works. By targeting the underlying causes of the signs of facial aging, it gradually and subtly corrects shallow to deep nasolabial folds (smile lines), contour deficiencies, and other facial wrinkles by replacing collagen lost during the aging process. This can give you a refined, more youthful-looking appearance.

The average number of Sculptra® Aesthetic treatment sessions is 3 injections over a three months

  • 80% of patients satisfied with treatment at 25 months
  • Adverse events were mostly mild-to-moderate in severity and were typical of dermal filler injections